ArticleFrontiers in immunology2021
Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).Revista da Sociedade Brasileira de Medicina Tropical · 2023Trial
- Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows.Cell reports methods · 2026Article
- Regulatory T cells in hypoxic environments.Frontiers in immunology · 2026Review
- Early Diagnosis and Monitoring of Adaptive Immune Response in a Cohort of Mild Mpox Patients During the 2022 Wave.Microorganisms · 2025Article
- Longitudinal immune profiling uncovers regulatory T cell signatures associated with the progression of COVID-19.Frontiers in immunology · 2025Article
- Heterogeneity and longitudinal transcriptomic characteristics of Tregs in COVID-19 patients.Frontiers in immunology · 2025Article
- T Regulatory Cell Subsets Do Not Restore for One Year After Acute COVID-19.International journal of molecular sciences · 2024Article
- Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.Journal of translational medicine · 2024Article
- Peripheral Blood Mononuclear Cells and Serum Cytokines in Patients with Lupus Nephritis after COVID-19.International journal of molecular sciences · 2024Article
- Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect.Acta pharmaceutica Sinica. B · 2024Article
- The Renin-Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic.Microorganisms · 2024Review
- Article
- Article
- Responses of Helper T Cell Subsets at Diagnosis and After Discharge in Patients with Non-Severe COVID-19: A Prospective Observational Study.Journal of clinical practice and research · 2024Article
- Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.Vaccines · 2023Review
- Donor selection for adoptive cell therapy with CD45RACytotherapy · 2023Article
- Epigenetic immune monitoring for COVID-19 disease course prognosis.Frontiers in immunology · 2023Article
- Differential regulatory T cell signature after recovery from mild COVID-19.Frontiers in immunology · 2023Article
- Predictors of COVID-19 Severity in Elderly Patients Infected by Omicron in China, 18 December 2022-5 February 2023.Infection and drug resistance · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify. Methods: We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses. Results: The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4 Conclusions: The present study demonstrates the association between CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.